Polish study tracks Real-Life results of rare blood disorder treatment
NCT ID NCT06633536
Summary
This study is collecting information on how well the medication ravulizumab works for Polish adults with paroxysmal nocturnal hemoglobinuria (PNH) in real-world clinical practice. Researchers will follow 64 patients who are already receiving this treatment through Poland's national drug program. The study aims to understand treatment outcomes by measuring blood markers and transfusion needs over time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Bialystok, Poland
-
Research Site
Brzozów, Poland
-
Research Site
Bydgoszcz, Poland
-
Research Site
Gdansk, Poland
-
Research Site
Krakow, Poland
-
Research Site
Lodz, Poland
-
Research Site
Lublin, Poland
-
Research Site
Opole, Poland
-
Research Site
Szczecin, Poland
-
Research Site
Warsaw, Poland
-
Research Site
Wałbrzych, Poland
Conditions
Explore the condition pages connected to this study.